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ABSTRACT 
 
Aims: We describe the case of a patient with glioblastoma (GBM) who developed severe and 
prolonged myelosuppression during concomitant daily temozolomide (TMZ) and radiotherapy (RT) 
Case Study 
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treatment. Analysis of polymorphisms in genes correlated with TMZ-induced myelotoxicity was also 
performed. 
Presentation of the Case: A 67–year-old man with diagnosis of GBM undergoing concomitant RT-
TMZ treatment developed severe and prolonged pancytopenia that led to discontinuation of TMZ 
and required frequent platelet and red cells transfusions. Analysis of single nucleotide 
polymorphisms (SNPs) in the genes NAD(P)H dehydrogenase, quinone 1 (NQO1) and glutathione 
S-transferase pi 1 (GSTP1) was carried out. Both SNPs were found to be wild-type. 
Discussion: TMZ is an oral alkylating agent used for the treatment of glioblastoma. TMZ is usually 
considered well tolerated and safe, with nausea and mild myelosuppression being the most 
common side effects. However, severe haematologic adverse events have been also reported. 
Recently, there has been growing interest in gene polymorphisms that might be associated with an 
increased risk of hematologic toxicity.  
Conclusion: Myelosuppression is a side effect that can occur relatively early during concomitant 
TMZ treatment and can negatively impact on patient’s quality of life. Further studies are warranted 
to find out a correlation between genetic factors and the occurrence of severe hematologic toxicity. 
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ABBREVIATIONS 
 
GBM: Glioblastoma multiforme, TMZ: Temozolomide, RT: radiotherapy. 
 
1. INTRODUCTION 
 
Glioblastoma multiforme (GBM) is the most 
common malignant primary brain tumor in adults. 
The standard treatment for newly diagnosed 
glioblastoma consists of maximum safe surgical 
resection followed by radiotherapy (RT) with 
concomitant and adjuvant chemotherapy with 
Temozolomide (TMZ) [1]. The use of TMZ, an 
oral alkylating agent, in association with RT can 
improve overall survival of patients with GBM     
[1-2]. TMZ is relatively safe and generally well-
tolerated. However, severe haematologic 
adverse events have been reported in several 
case reports and small series [3-11]. Recently, 
there has been growing interest in the analysis of 
gene polymorphisms that might be associated 
with an increased risk of hematologic toxicity   
[12-15]. 
 
We describe the case of a patient with GBM who 
developed severe and prolonged 
myelosuppression during concomitant daily TMZ 
and radiotherapy treatment. Analysis of 
polymorphisms in genes correlated with TMZ-
induced myelotoxicity was also performed. 
 
2. PRESENTATION OF THE CASE  
 
A 67–year-old man with a history of arterial 
hypertension was admitted to the emergency 
department with paresthesias of the left upper 
extremity.Magnetic resonance imaging of the 
brain showed an enhancing solid mass (20 mm) 
in the right parietal lobe and diffuse signal 
hyperintensity on T2-weighted images in the right 
hemisphere suggestive of gliomatosis cerebri 
(Fig. 1). The patient subsequently underwent a 
right temporal craniotomy and subtotal excision 
of the mass. The histopathological findings of the 
tumor were consistent with the diagnosis of 
GBM. Molecular analysis revealed methylation of 
the O6-methylguanine-DNA-methyltransferase 
(MGMT) gene promoter in the tumor sample. 
 
The patient was put on antiepileptic medication 
with levetiracetam and referred to us for adjuvant 
treatment. He began treatment with RT and 
concomitant daily TMZ at a dose of 140 mg/die 
(75 mg/m2). The planned RT dose was of 59.4 
Gy to be given in 33 fractions of 1.8 Gy. Prior to 
treatment the patient had a white blood cell 
(WBC) and platelet (PLT) count of 8.8 x 103/uL 
and 197 x 103/uL, respectively. He did not 
receive co-Trimoxazole prophylaxis. During 
treatment, complete blood count (CBC) was 
carried out regularly once a week. He tolerated 
the combined therapy quite well, being mild 
fatigue the main side effect. After 21 of 33 
planned fractions of radiation therapy and 30 of 
47 days of TMZ, a platelet count of 11 x 103/uL 
was found. TMZ and RT were immediately 
stopped. One week later, when the platelet count 
dropped to 8 x 103/uL and multiple petechiae 
appeared on the trunk and arms, he was 
hospitalized in the medical oncology department. 
During hospitalization he became pancytopenic 
and required repeated platelet and red cell 
transfusions. He was treated with growth factors, 
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Fig. 1. Brain MRI of the patient at diagnosis 
a) Enhanced lesion in the right parietal lobe on axial T1-weighted contrast image. b) Diffuse signal  
hyperintensity on axial T2-weighted image. 
 
Table 1. Haematologic parameters over time 
 
 Platelets WBC  Hemoglobin 
(x 103/uL) (x 103/uL) (g/dl) 
Baseline values at the beginning of RT/TMZ 197 8.8 13.5 
Day 13 of RT/TMZ 140 7.8 14.4 
TMZ discontinuation (day 21 of RT/TMZ) 11 2.28 11.3 
Day 6 from TMZ discontinuation 12 0.16 9.4 
Day 9 from TMZ discontinuation 29 0.09 9.2 
Day 15 from TMZ discontinuation 16 0.26 8.0 
Day 22 from TMZ discontinuation 7 1.61 7.8 
Day 29 from TMZ discontinuation 11 2.14 7.9 
Day 41 from TMZ discontinuation 23 2.20 7.0 
Day 65 from TMZ discontinuation 34 4.3 9.8 
Day 125 from TMZ discontinuation 16 2.99 7.6 
Day 163 from TMZ discontinuation 16 2.77 8.4 
Day 206 from TMZ discontinuation 16 3.29 9.1 
Day 305 from TMZ discontinuation   34  4.03  9.8  
Day 402 from TMZ discontinuation   72 4.35  13.5 
Day 590 from TMZ discontinuation   130 3.60 9.3  
RT, radiotherapy; TMZ, temozolomide; WBC, white blood cell 
 
erythropoietin and antibiotics. Serum Epstein 
Barr virus and cytomegalovirus IgMtiters were 
undetectable. Vitamin B12 and folic acid levels 
were normal. The values of white blood cells, 
platelets and hemoglobin (Hb) during the whole 
period are shown in Table 1. 
 
The patient was discharged from the hospital 
after one month with partial recovery of blood 
values. He completed his course of RT without 
concomitant TMZ. No adjuvant treatment with 
TMZ was started. Because of persistent 
pancytopenia a bone marrow aspirate and biopsy 
were performed one month after the end of 
treatment. The marrow was hypocellular (5-10%) 
and the erytroid series was hyperplastic with 
marked signs of dysplasia. The granulopoietic 
and megakaryopoietic lineages were hypo-
b) a) 
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represented but without dysplasia. Several 
plasma cells with reactive features were 
observed in the marrow interstitium. Cytogenetic 
analysis showed a normal karyotype. Analysis of 
single nucleotide polymorphisms (SNPs) in the 
genes NAD(P)H dehydrogenase, quinone 1 
(NQO1; rs1800566) and glutathione S-
transferase pi 1 (GSTP1; rs1695) was carried out 
as previously described by Sylvester et al. [16].  
Both SNPs were found to be wild-type (Table 2). 
 
Table 2. Genotyping results 
 
SNPs Increased 
risk 
Global 
frequencies [19] 
GSTP1 
(rs1695) 
AG AA AA: 0.33, AG: 
0.55, GG: 0.12 
NQO1 
(rs1800566) 
AA GG GG: 0.60, AG: 
0.37, AA: 0.03 
SNPs, single nucleotide polymorphisms; GSTP1, 
glutathione S-transferases pi 1; NQO1, NAD(P)H 
dehydrogenase (quinone) family. 
 
No further treatment was administered until 20 
months from GBM diagnosis when, following 
disease progression, the patient underwent a 
second course of RT (37.5 Gy in 15 fractions of 
2.5 Gy) without TMZ. MRI of the brain performed 
one month after the end of RT showed further 
tumor progression and the patient died two years 
after the initial diagnosis of GBM. The values of 
the last CBC were: WBC: 3.6 x 103/uL; PLT: 130 
x 103/uL; Hb: 9.3 g/dl.  
 
3. DISCUSSION 
 
TMZ is an oral alkylating agent with activity 
against brain tumors. TMZ is usually considered 
well tolerated and has a good toxicity profile. The 
cytotoxic effect of TMZ is caused by the 
generation of O6-methylguanine DNA adducts; 
when the enzymes of the mismatch repair 
system attempt to repair this alteration, the 
mechanism of apoptosis is activated. 
Myelosuppression is the most common 
haematologic adverse event of TMZ but it is a 
non-cumulative and reversible effect, and bone 
marrow recovery usually occurs within 28 days 
[17]. However, severe myelosuppression has 
been also reported. In the phase III trial of the 
European Organisation for Research and 
Treatment of Cancer (EORTC) and National 
Cancer Institute of Canada Clinical Trials Group 
(NCIC) of RT with concomitant and adjuvant 
TMZ in patients with newly diagnosed GBM, 
Stupp et al. [1] reported a 16% rate of grade 3-4 
myelosuppression. Grade 3-4 thrombocytopenia 
was observed in 3% and 11% of patients during 
concomitant and adjuvant treatment, 
respectively. Higher rates of myelotoxicity were 
reported by other authors. Doyle et al. [3] 
observed a 19% rate of severe 
myelosuppression in 16 patients with GBM 
treated with concomitant daily TMZ and RT. In a 
series of 52 patients with newly diagnosed high-
grade gliomas receiving RT with concomitant and 
adjuvant TMZ, Gerber et al. [4] reported a 25% 
rate of grade 3-4 myelosuppression and 19% of 
grade 3-4 thrombocytopenia that caused 
discontinuation of treatment in 17% of patients. 
More recently, Villano et al. [18] reviewed all the 
TMZ-associated haematologic adverse events 
reported in the FDA Med-Watch database 
between 1997 and 2008, and they identified 228 
cases of pancytopenia. Death occurred in 56 
patients because of pancytopenia or its 
complications. The median duration of TMZ 
treatment was less than 3 weeks. Most of the 
cases were diagnosed within a week from the 
end of combined RT-TMZ treatment and, in 59 
patients, during concomitant TMZ treatment, as 
in our case. 
 
The association between genetic alterations in 
genes involved in DNA repair and drug 
metabolism and the risk of severe 
myelosuppression has been addressed in 
several studies [12-15]. Armstrong et al. [13] 
observed that the presence of the A allele of 
NQO1 and of the G allele of GSTP1 decreased 
the risk of toxicity. Reduced levels of NQO1 
could lead to reduced activation of TMZ, while 
the relationship between GSTP1 and 
myelotoxicity is not explained. Moreover, the 
presence of the G allele of MGMT in peripheral 
blood cells resulted in a significant increase in 
risk of toxicity, as a result of lower DNA repair 
and increased DNA damage. In our case, it was 
possible to perform only analysis of NQO1 and 
GSTP1 polymorphisms but not of MGMT. Both 
SNPs were found to be wild-type and no 
conclusions can be drawn from these findings. 
Data from a greater number of patients could 
help in treatment decision. However, currently 
genetic analysis is not routinely performed at our 
institution. 
 
4. CONCLUSION 
 
In conclusion, our case shows that severe and 
prolonged myelosuppression is a side effect that 
can occur relatively early during concomitant 
TMZ treatment and can negatively impact on 
patient’s quality of life. Physicians should be 
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aware of this potential long-term complication 
and should carefully evaluate hematopoietic 
function during TMZ treatment in order to 
eventually detect early bone marrow failure. 
Further studies are warranted to find out a 
correlation between genetic factors and the 
occurrence of severe hematologic toxicity. 
 
CONSENT 
 
Written consent for publication of case details 
was obtained from the patient’s next of kin. 
 
ETHICAL APPROVAL 
 
Not applicable. 
 
COMPETING INTERESTS 
 
Authors have declared that no competing 
interests exist. 
 
REFERENCES 
 
1. Stupp R, Mason WP, van den Bent MJ, 
Weller M, Fisher B, Taphoorn MJ, et al. 
Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. N 
Engl J Med. 2005;352(10):987-96. 
2. Stupp R, Hegi ME, Mason WP, van den 
Bent MJ, Taphoorn MJ, Janzer RC, et al. 
Effects of radiotherapy with concomitant 
and adjuvant temozolomide versus 
radiotherapy alone on survival in 
glioblastoma in a randomised phase III 
study: 5-year analysis of the EORTC-NCIC 
trial. Lancet Oncol. 2009;10(5):459-66. 
3. Doyle TJ, Mikkelsen T, Croteau D, Ali H, 
Anderson J, Beasse R, et al. Fatal 
hematologic toxicity with prolonged 
continuous administration of temozolomide 
(TMZ) during radiation therapy (RT) in the 
treatment of newly-diagnosed glioblastoma 
multiforme (GBM): Report of a phase II 
trial. J Clin Oncol. 2005;23:1546.  
4. Gerber DE, Grossman SA, Zeltzman M, 
Parisi MA, Kleinberg L. The impact of 
thrombocytopenia from temozolomide and 
radiation in newly diagnosed adults with 
high-grade gliomas. Neuro Oncol. 
2007;9(1):47-52. 
5. Morris EB, Kasow K, Reiss U, Ellison D, 
Broniscer A. Bone marrow transplantation 
for severe aplastic anemia secondary to 
temozolomide. J Neurooncol. 2009;91(2): 
237-39. 
6. Kopecký J, Priester P, Slovácek L, Petera 
J, Kopecký O, Macingova Z. Aplastic 
anemia as a cause of death in a patient 
with glioblastoma multiforme treated with 
temozolomide. Strahlenther Onkol. 
2010;186(8):452-57. 
7. Comez G, Sevinc A, Sever ON, Babacan 
T, Sarı I, Camci C. An unusual case of 
aplastic anemia caused by temozolomide. 
Case Report Med. 2010;2010:975039. 
8. Villano JL, Collins CA, Manasanch EE, 
Ramaprasad C, van Besien K. Aplastic 
anemia in patient with glioblastoma 
multiforme treated with temozolomide. 
Lancet Oncol. 2006;7(5):436-38. 
9. Noronha V, Berliner N, Ballen KK, Lacy J, 
Kracher J, Baehring J, et al. Treatment-
related myelodysplasia/AML in a patient 
with a history of breast cancer and an 
oligodendroglioma treated with 
temozolomide: case study and review of 
the literature. Neuro Oncol. 2006;8(3):280-
83. 
10. Kim SJ, Park TS, Lee ST, Song J, Suh B, 
Kim SH, et al. Therapy-related 
myelodysplastic syndrome/acute myeloid 
leukemia after treatment with 
temozolomide in a patient with 
glioblastoma multiforme. Ann Clin Lab Sci. 
2009;39(4):392-98. 
11. Hegi ME, Diserens AC, Gorlia T, Hamou 
MF, de Tribolet N, Weller M, et al. MGMT 
gene silencing and benefit from 
temozolomide in glioblastoma. N Engl J 
Med. 2005;352(10):997-1003. 
12. Nagane M, Nozue K, Shimizu S, Waha A, 
Miyazaki H, Kurita H, et al. Prolonged        
and severe thrombocytopenia with 
pancytopenia induced by radiation-
combined temozolomide therapy in a 
patient with newly diagnosed glioblastoma-
-analysis of O6-methylguanine-DNA 
methyl transferase status. J Neurooncol. 
2009;92(2):227-32. 
13. Armstrong TS, Cao Y, Scheurer ME, Vera-
Bolaños E, Manning R, Okcu MF, et al. 
Risk analysis of severe myelotoxicity with 
temozolomide: the effects of clinical and 
genetic factors. Neuro Oncol. 
2009;11(6):825-32. 
14. Schaich M, Kestel L, Pfirrmann M, Robel 
K, Illmer T, Kramer M, et al. A MDR1 
(ABCB1) gene single nucleotide 
polymorphism predicts outcome of 
temozolomide treatment in glioblastoma 
patients. Ann Oncol. 2009;20(1):175-81. 
  
 
 
Scaringi et al.; IJMPCR, 2(4): 95-100, 2015; Article no.IJMPCR.2015.019 
 
 
 
100 
 
15. Lombardi G, Rumiato E, Bertorelle R, 
Saggioro D, Farina P, Della Puppa A, et al. 
Clinical and genetic factors associated with 
severe hematological toxicity in 
glioblastoma patients during radiation plus 
temozolomide treatment: a prospective 
study. Am J Clin Oncol. Epub; 2013.  
16. Sylvester RK, Steen P, Tate JM, Mehta M, 
Petrich RJ, Berg A, et al. Temozolomide-
induced severe myelosuppression: 
analysis of clinically associated 
polymorphisms in two patients. Anticancer 
Drugs. 2011;22(1):104-10. 
17. Birner A. Pharmacology of oral 
chemotherapy agents. Clin J Oncol Nurs. 
2003; 7(6 Suppl):11-9.  
18. Villano JL, Letarte N, Yu JM, Abdur S, 
Bressler LR. Hematologic adverse events 
associated with temozolomide. Cancer 
Chemother Pharmacol. 2012;69(1):107-
113. 
19. Collins FS, Brooks LD, Chakravarti A. A 
DNA polymorphism discovery resource for 
research on human genetic variation. 
Genome Res. 1998;8(12):1229-31. 
Erratum in: Genome Res. 1999;9(2):210. 
_________________________________________________________________________________ 
© 2015 Scaringi et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
 
 
 
 
Peer-review history: 
The peer review history for this paper can be accessed here: 
http://www.sciencedomain.org/review-history.php?iid=785&id=38&aid=6767 
 
